Abstract Search

ea0073aep218 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Utilisation of fibrosis-4 (fib-4 score) for screening non-alcoholic fatty liver disease (nafld) in women with type 2 diabetes (t2dm) in real world setting

Padhye Dakshata , Tanna Snehal , James Aleyamma , Nair Nithya

IntroductionLimited evidence exists for hepatic fibrosis in Type 2 Diabetes (T2DM). NAFLD is an independent risk factor for incident diabetes with trends towards increased risk in women.MethodsWe conducted a cross-sectional, retrospective analysis in 438 women with T2DM.FIB-4 score was used to estimate extent of incidental finding of liver fibrosis.ResultsMean fib...

1 shares

ea0081p315 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Participation in Diabefly® digital therapeutics program leads to significant improvement in glycemic control and reduction in weight and BMI among people with T2D

Verma Ritika , Khader Mohammed , Lathia Tejal , Tanna Snehal , Saraf Amit , Thakkar Piya Ballani , Raskar Vivek , Selvan Chitra , Guntur Saimala , Singal Arbinder

Background: People with chronic metabolic conditions such as type 2 diabetes (T2D) encounter challenges with self-management regimens to improve their glycemic control, weight and as well as to reduce complications associated with diabetes. Optimal management of T2D requires regular monitoring by physician, access to multidisciplinary care and achieving target HbA1c without hypoglycemia. Digital therapeutics (DTx) provide highly accessible, cost-effective, evidence-based solut...

2 shares

Endocrine Abstracts

Utilisation of fibrosis-4 (fib-4 score) for screening non-alcoholic fatty liver disease (nafld) in women with type 2 diabetes (t2dm) in real world setting

Participation in Diabefly® digital therapeutics program leads to significant improvement in glycemic control and reduction in weight and BMI among people with T2D

BiosciAbstracts